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Abstract
Objectives—To examine whether pre-heart failure (HF) myocardial injury explains the 
differential mortality after HF across weight categories.
Background—Obesity is a risk factor for HF, but pre-HF obesity is associated with lower 
mortality after incident HF. High-sensitivity Troponin T (hs-cTnT), a sensitive marker of 
myocardial injury, predicts incident HF and mortality.
Methods—Stratifying 1279 individuals with incident HF hospitalizations by their pre-HF hs-
cTnT levels (< and ≥ 14 ng/L), we examined the association of pre-HF body mass index (BMI) 
with mortality after incident HF hospitalization in the ARIC study.
Corresponding author: Anita Deswal, MD, MPH, Michael E. DeBakey VA Medical Center &Baylor College of Medicine, VAMC 
(111B), 2002 Holcombe Blvd., Houston, TX 77030, Phone: 713 794 7441, Fax: 713-794-8802; adeswal@bcm.edu. 
Disclosures:
1. Drs. Ballantyne, Hoogeveen and Nambi- Research Grant: Significant; Roche to help with measurement of assays. Other: 
Modest; Biomarkers to Improve Prediction of Heart Failure Risk: patent no. 61721475. Filed by Roche, Baylor College 
of Medicine along with 4 investigators including Drs. Ballantyne, Hoogeveen and Nambi.
2. Dr. Ballantyne – consultant, Roche.
3. Dr. Selvin- advisory board, Roche.
4. Others: None
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
JACC Heart Fail. Author manuscript; available in PMC 2018 January 01.
Published in final edited form as:
JACC Heart Fail. 2017 January ; 5(1): 56–63. doi:10.1016/j.jchf.2016.10.010.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Results—Mean age at HF was 74 years (53% women, 27% black). Individuals with pre-HF hs-
cTnT≥14 ng/L had higher mortality after incident HF (HR 1.46, 95% CI 1.18-1.80) compared to 
individuals with hs-cTnT<14 ng/L in an adjusted model including BMI. Compared with normal 
weight, the mortality was lower in overweight (HR 0.69, 95% CI 0.48-0.98) and obese (HR 0.50, 
95% CI 0.35-0.72) with hs-cTnT<14 ng/L; and in those with hs-cTnT ≥14 ng/L (overweight: HR 
0.50, 95% CI 0.30-0.83; obese: HR 0.56, 95% CI 0.34-0.91) (interaction p=0.154 between BMI 
and hs-cTnT). The lower mortality risk in obese and overweight remained similar when log hs-
cTnT was added as a continuous variable to a multivariable model and in sensitivity analyses 
adjusting for left ventricular hypertrophy and high-sensitivity C-reactive protein.
Conclusion—Although greater pre-existing subclinical myocardial injury was associated with 
higher mortality after incident HF hospitalization, it did not explain the obesity paradox in HF, 
which was observed irrespective of subclinical myocardial injury.
Keywords
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Introduction
Obesity and overweight affect about two-thirds of the U.S. population (1). Obesity is 
associated with an increased risk of heart failure (HF) (2,3). Paradoxically, once HF 
develops, obesity is associated with better prognosis (4-7). Using the Atherosclerosis Risk In 
Communities (ARIC) study, we previously showed that individuals who were overweight 
and obese (using pre-HF body mass index, BMI) before the onset of incident HF 
hospitalization also had lower mortality after HF development, compared to those with 
normal BMI, independent of demographics and comorbidities, including cancer, smoking 
and diabetes (8). Our findings suggested that weight loss from advanced HF did not 
completely explain the survival benefit associated with higher BMI in HF patients. One 
potential explanation for this obesity paradox is that the HF patients who are able to preserve 
their weight may represent a non-catabolic subgroup with different neurohormonal, 
inflammatory and metabolic profiles (9). However, there may also be heterogeneity in the 
degree of myocardial injury in obese individuals who present with the constellation of 
symptoms and signs such as shortness of breath and fluid retention, leading to a diagnosis of 
HF.
Cardiac troponin T measured using a high-sensitivity assay (hs-cTnT) is a sensitive marker 
of subclinical myocardial injury (10). We have shown that hs-cTnT predicts incident HF in 
the ARIC study (11). Other studies of community dwelling, otherwise asymptomatic 
individuals have also demonstrated similar findings (12,13). Furthermore, higher levels of 
hs-cTnT were also associated with increased cardiac and all-cause mortality (11-13), and 
higher degree of myocardial dysfunction (13). We postulated that hs-cTnT measured before 
incident HF would be helpful in identifying overweight and obese individuals at varying risk 
for adverse outcomes after the development of the clinical HF syndrome. Undetectable or 
low levels of hs-TnT may therefore identify ‘cardiac biomarker-healthy’ obese individuals 
with lower degree of myocardial injury in whom symptoms of HF such as shortness of 
breath and edema are driven mostly by non-cardiac obesity-related mechanisms, and who 
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would therefore have a good prognosis contributing to the obesity paradox. In contrast, 
‘cardiac biomarker-unhealthy’ obese, in whom HF is driven to a greater extent by 
myocardial injury/dysfunction as indexed by hs-cTnT, would be expected to have a poor 
prognosis. We postulated that the obesity paradox will be observed in “biomarker-healthy 
obese” individuals but not in the “biomarker-unhealthy obese”, as stratified by levels of hs-
cTnT prior to incident HF. Accordingly, we examined the risk of mortality associated with 
pre-HF BMI and hs-cTnT in individuals who subsequently had incident HF hospitalization 
in the ARIC study.
Methods
Study population
The ARIC study is an ongoing prospective cohort study of 15,792 individuals enrolled from 
four U.S. communities: Washington County, Maryland; Jackson, Mississippi; Forsyth 
County, North Carolina; and suburbs of Minneapolis, Minnesota (14). The baseline 
evaluation (Visit 1) of individuals aged 45-64 years, took place between 1987 and 1989. 
Participants were subsequently examined at three follow-up visits at approximately 3 year 
intervals, and after an extended interval, a fifth study visit was recently completed between 
2011 and 2013. The design, recruitment and examination protocols for the ARIC study has 
been described in detail previously (14). The institutional review boards at each site 
approved all study protocols, and informed consent was provided by all study participants. 
The authors are solely responsible for the design, conduct and analyses of the study and the 
drafting, editing and preparation of the final version of the manuscript. Visit 4 (1996-1998), 
at which hs-cTnT was measured for all participants, was the baseline for the current 
analysis. Of 11,656 ARIC Visit 4 participants, 1,279 individuals who had an incident HF 
hospitalization at least 6 months after Visit 4 were eligible for this analysis after exclusions 
as detailed in Figure 1.
Measurement of hs-cTnT
The details regarding the hs-cTnT assay have been previously published (11). Briefly, hs-
cTnT was measured in 2010 on blood samples collected during ARIC Visit 4 with a high-
sensitivity assay, Elecsys Troponin T (Roche Diagnostics®), on an automated Cobas e411 
analyzer. The 99th percentile value for the hs-cTnT measured in a healthy reference 
population (aged 20–70) was 14 ng/L (Roche Diagnostics®, data on file).
Baseline variables
Measurements were taken in standard scrub attire with no shoes. Weight was measured 
using a scale that was zeroed daily and calibrated quarterly. BMI assessment was performed 
at the time of hs-cTnT measurement. Pre-HF BMI was defined as the BMI measurement 
from ARIC Visit 4, which was at least 6 months before the date of incident HF 
hospitalization (8). Patients with HF were categorized by the pre-HF BMI into normal 
weight (18.5 to <25 kg/m2), overweight (25 to <30 kg/m2), and obese (≥30 kg/m2) groups. 
Patients in the underweight category (BMI <18.5 kg/m2; n=83) were excluded because of 
small numbers and the possible presence of other comorbidities leading to lower BMI (8).
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The ascertainment of demographics and comorbidities at each study visit has been described 
previously (14). Age was assessed at the time of incident HF hospitalization, and sex, race 
and education levels were obtained at ARIC Visit 1 from interviewer-administered 
questionnaires. Physical activity was assessed at ARIC Visit 3 using the sport index of the 
Baecke Questionnaire (15). Baecke sport activity score ranges from 1-5 with a higher score 
indicating higher physical activity (16). Comorbidities such as hypertension, diabetes, 
cancer, history of coronary heart disease (CHD), stroke and transient ischemic attacks were 
assessed as present if the conditions were documented to be present at any pre-HF ARIC 
visit. All other baseline variables were obtained from Visit 4. Diabetes was defined as 
fasting blood glucose level ≥126 mg/dL, non-fasting blood glucose level ≥200 mg/dL, or 
self-reported physician diagnosis of or treatment for diabetes. Total cholesterol and high-
density lipoprotein cholesterol were determined by enzymatic methods. Estimated 
glomerular filtration rate was computed using the Modification of Diet in Renal Disease 
study equation (17). Blood pressure was measured twice and the average of the two 
measurements was used. Hypertension was defined as systolic blood pressure ≥140 mmHg, 
diastolic blood pressure BP ≥90 mmHg measured with random-zero mercury manometers or 
use of antihypertensive medications. Details of ascertainment of CHD and stroke have been 
described previously (18-20).
Ascertainment of HF and All-Cause Mortality
ARIC investigators conduct continuous, comprehensive surveillance for all cardiovascular 
(CV) disease-related hospitalizations and deaths in the 4 communities. Incident HF 
hospitalization was determined using annual interviews with study participants regarding 
interim hospitalizations (response rate: 93-96%), review of discharge lists from local 
hospitals and survey of health department death certificate files and the national death index. 
In the ARIC cohort, incident HF was defined as the first occurrence of either a 
hospitalization that included an International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) discharge diagnosis code for HF beginning with “428” 
(ie, 428.0 to 428.9) in any position or a death certificate ICD-9 code beginning with “428” 
(HF) or ICD-10 code “I50” (HF or I50.0 to I50.9) in any position (8,21). Deaths were 
confirmed by review of hospital discharge records for inpatient deaths and death certificates 
for deaths outside the hospital.
Statistical Analysis
The outcome of interest was all-cause mortality in individuals who had incident HF 
hospitalization. For this study only incident HF ascertained ≥ 6 months after ARIC Visit 4 
until December 31, 2011 was included because this was the last date for which follow up 
was available at the time the study was designed. The last HF hospitalization occurred on 
December 29, 2011. Eligible study participants with incident HF hospitalization were 
followed up for death up to 5 years after incident HF hospitalization or until December 31, 
2011. Categorical variables were compared between groups using Chi-square tests and 
continuous variables were compared using the analysis of variance test (ANOVA). To 
accommodate for the wide range of follow-up duration, we calculated survivor function in 
the overall population and within BMI and hs-cTnT categories using survival estimate from 
Cox proportional hazard model. The survivor function estimates the proportion of patients 
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surviving at any time point. We assessed the associations between pre-HF BMI categories 
(normal weight, overweight and obese) and all-cause mortality after HF in a model adjusted 
for age, gender, race, education level, health insurance, systolic blood pressure, physical 
activity, total cholesterol, current smoking, current alcohol use, estimated glomerular 
filtration rate, diabetes mellitus, hypertension, history of CHD, stroke/transient ischemic 
attack and cancer using Cox proportional hazards model (Model 1). Subsequently, we added 
log-transformed hs-cTnT as a continuous variable to the model above. We selected 
covariates a priori based on previous knowledge of potentially important variables (8). We 
also examined hazard ratios (HRs) for all-cause mortality by pre-HF BMI and hs-cTnT, with 
hs-cTnT as two (< or ≥14 ng/L) categories. This cutoff for hs-cTnT was chosen because hs-
cTnT=14 ng/L corresponds to the 99th percentile in a healthy reference population as 
provided by the assay manufacturer, and has been used in prior analyses (11,20,22). We 
examined the interaction between BMI and hs-cTnT categories and between BMI category 
and hs-cTnT as a continuous variable (log-transformed).. We also assessed the hazard ratios 
for death in individuals with pre-HF hs-cTnT ≥14 ng/L compared to hs-cTnT<14 using 
Model 1 plus BMI (treated as ordinal variable, i.e., normal weight, overweight and obese). 
The proportional hazards assumption was examined using time-dependent covariates and 
likelihood ratio statistics. When the proportionality assumption was violated, a time-
dependent term, the product of BMI/hs-cTnT group and log time was added to the model 
(8). In addition, we performed some sensitivity analyses. We developed additional models 
where we further adjusted Model 1 with left ventricular hypertrophy as determined by 
Cornell voltage electrocardiographic criteria (data available for 976 out of the 1279 
individuals in the study cohort) and with high-sensitivity C-reactive protein (data available in 
1176 individuals). All presented tests were 2-tailed and a p value <0.05 was considered 
statistically significant. All analyses were performed using SAS version 9.3 (Cary, NC) and 
STATA version 12 (College Station, TX).
Results
Baseline characteristics
The final study cohort consisted of 1,279 individuals with incident HF hospitalization whose 
BMI and hs-cTnT were measured at least 6 months before incident HF. The pre-HF BMI 
and hs-cTnT were both measured at a median of 8.3 (25th, 75th percentile 5.0, 11.4) years 
before the HF diagnosis. The mean age was 74 years at the time of incident HF 
hospitalization, 53% of the participants with HF were women, 27% were black, 17% had 
normal weight, 35% were overweight and 48% were obese.
Compared to individuals with lower pre-HF hs-cTnT levels, those with higher hs-cTnT 
levels developed HF at a slightly younger age, were more often men, had more 
comorbidities such as hypertension, diabetes, history of myocardial infarction, CHD, left 
ventricular hypertrophy and cancer, had lower levels of estimated glomerular filtration rate, 
total and high-density lipoprotein cholesterol, but higher levels of triglycerides, high-
sensitivity C-reactive protein and NT-proBNP, and had a shorter time to development of HF; 
however, fewer of them were smokers (Table 1). There was no difference in hemoglobin 
levels, heart rate and physical activity by hs-cTnT categories. The mean BMI was similar in 
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both hs-cTnT groups. Baseline characteristics by pre-HF BMI groups are described in 
Supplemental Table 1. Briefly, individuals in higher BMI categories developed HF at a 
relatively younger age, were more likely to be black, more often had diabetes and 
hypertension, were less likely to be current smokers and alcohol users, had higher levels of 
pre-HF high-sensitivity C-reactive protein but lower levels of pre-HF NT-proBNP, but had 
no difference in the time to incident HF and in the prevalence of pre-existing CHD and 
history of MI.
Mortality
A total of 579 among 1279 individuals (45.3%) who developed HF died within 5 years after 
incident HF hospitalization [survival estimate 0.48 (0.45-0.51)]. Overall, overweight and 
obese groups had better survival over 5 years after HF (Supplemental Figure and 
Supplemental Table 2) compared with normal weight group. Similarly, individuals with hs-
cTnT <14 ng/L had better survival than those with hs-cTnT ≥14 ng/L (Supplemental Table 
2).
After incident HF hospitalization, overweight and obese individuals had better survival 
compared with normal-weight people in groups with either hs-cTnT <14 or ≥14 ng/L 
(Figure 2 and Supplemental Table 2). In individuals with hs-cTnT≥14 ng/L, the Kaplan-
Meier survival curves for obese and overweight groups overlapped eventually, however, the 
normal weight group curve was separated throughout follow-up.
After adjusting for demographics and CV risk factors/disease, overweight and obese HF 
individuals had lower mortality compared to normal weight HF cohort members in both the 
groups with hs-cTnT<14 and with hs-cTnT≥14 ng/L (Table 2; p= 0.154 for interaction 
between BMI and hs-cTnT). For example, obese individuals with hs-cTnT<14 ng/L had 
50% lower relative mortality risk than those with normal weight and hs-cTnT<14 ng/L [HR 
0.50 (95% CI: 0.35-0.72)]; and obese individuals with hs-cTnT≥14 ng/L had 44% lower 
relative mortality risk than those with normal weight and hs-cTnT≥14 ng/L [HR 0.56 
(0.34-0.91)]. When all the 6 possible groups resulting from BMI and hs-cTnT categories 
were compared with normal weight and hs-cTnT<14 ng/L as the reference, the highest 
mortality was observed in normal weight and hs-cTnT≥14 ng/L (HR 1.50), and the lowest 
mortality was seen in obese and hs-cTnT<14 ng/L (HR 0.50) (Figure 3). In the current data, 
we again observed that pre-morbidly overweight and obese individuals who subsequently 
developed HF had reduced mortality risk after HF compared with normal weight individuals 
after adjusting for demographics and CV risk factors/disease (Model 1, Supplemental Table 
3). Results were similar when we further adjusted the model with hs-cTnT (log-transformed) 
as a continuous variable (Model 2, Supplemental Table 3; p= 0.635 for interaction between 
BMI and log hs-cTnT) with no appreciable difference in the hazard ratios between models, 
which did or did not include hs-cTnT. In additional analyses, individuals with hs-cTnT≥14 
ng/L had greater risk for death (1.46, 1.18-1.80) when compared to individuals with hs-
cTnT<14 in Model 1 plus BMI categories.
Results of sensitivity analyses were similar to those of the main analyses (Supplemental 
Tables 4-5). When the models examining risk of mortality based on BMI categories within 
the higher and lower troponin groups were further adjusted for either left ventricular 
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hypertrophy on electrocardiogram (n= 976) or high-sensitivity C-reactive protein (n=1176), 
the survival benefit for overweight/obese compared to normal weight individuals was still 
observed within the two troponin groups.
Discussion
In this study, we found that despite an increased risk for mortality with greater pre-existing 
subclinical myocardial injury, as assessed by hs-cTnT, the mortality risk was lower in 
overweight or obese individuals compared with normal weight individuals, regardless of 
preexisting subclinical myocardial injury. Furthermore, individuals with normal pre-HF 
weight and more advanced pre-HF subclinical myocardial injury (i.e., hs-cTnT≥14 ng/L) 
had the highest mortality after HF development.
Association of pre-HF hs-cTnT and Heart Failure
Using data from the ARIC cohort, it was recently shown that higher BMI was independently 
associated with a linear increase in myocardial injury as assessed using hs-cTnT (22). 
Furthermore, individuals with highest hs-cTnT who were also severely obese had a HR of 
9.2 for incident HF hospitalization compared to those with normal weight and undetectable 
hs-cTnT (22). Other studies have also demonstrated that obesity is independently associated 
with an increased risk of incident HF (2,3). Our results are in keeping with these 
observations by demonstrating that overweight and obese individuals with HF have higher 
level of subclinical myocardial injury several years before the development of HF 
(Supplemental Table 1).
Association of pre-HF hs-cTnT and Mortality in Heart Failure
Prior studies have demonstrated that increasing myocardial injury as indexed by hs-cTnT 
was associated with higher cardiac and all-cause mortality (11-13), and higher degree of 
myocardial dysfunction (13). In the current analysis, we have further demonstrated that 
higher myocardial injury several years before incident HF hospitalization is also associated 
with higher post-HF mortality. Among individuals with incident HF hospitalization, those 
with pre-HF hs-cTnT≥14 ng/L had 46% relative increase in mortality risk compared to those 
with hs-cTnT<14 ng/L in a model adjusting for BMI and other baseline variables.
Pre-HF Myocardial Injury and the Obesity Paradox
Once HF develops, obese individuals have lower mortality risk compared to normal weight 
individuals, i.e., the obesity paradox (4-8). Obesity and overweight measured before the 
onset of HF (pre-morbid BMI) have also been associated with lower mortality risk compared 
to normal weight individuals (8), suggesting that weight loss/cachexia after HF does not 
completely explain the lower mortality risk seen in obese HF patients, as was replicated in 
the current study. We had hypothesized that the obesity paradox may only be observed in 
individuals with lesser myocardial injury before HF where non-cardiac factors may 
contribute to the volume overload presenting as the HF syndrome in obese individuals 
(biomarker healthy obese); but the paradox would not be seen in a more homogenous group 
with higher pre-HF myocardial injury. However, our analysis found that the risk for death 
after HF decreased in overweight and obese compared to normal weight individuals 
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regardless of pre-existing sub-clinical myocardial injury in models stratified by hs-cTnT, as 
well as in models with hs-cTnT as a continuous variable. These results remained the same in 
sensitivty analyses which adjusted for pre-HF biomarkers of inflammation (high-sensitivity 
C-reactive protein) and for ventricular structure (left ventricular hypertrophy by 
electrocardiogram). Taken together, our findings suggest that the obesity paradox in HF may 
not be explained by pre-HF “biomarker-healthy” or “biomarker-unhealthy” obesity, using 
the biomarkers examined in this study. Previously, higher levels of tumor necrosis factor 
alpha, adiponectin and higher systolic pulmonary arterial pressure have been associated with 
lower BMI compared to those with higher BMI in HF patients (23). Future studies will need 
to explore whether these and other cardiac and non-cardiac factors associated with obesity 
such as presence of greater metabolic reserve, attenuated neurohormonal activation, or other 
biomarkers, such as higher levels of soluble tumor necrosis factor receptors available to bind 
harmful circulating tumor necrosis factor, or just a lead time bias with earlier presentation of 
clinical HF, contribute to the obesity paradox as noted in HF as well as in other chronic 
conditions (24-27).
Clinical Implications
Although differential levels of pre-HF hs-cTnT do not explain the obesity paradox, the 
higher incidence of HF and higher mortality after HF that is associated with higher levels of 
troponin measured several years before incident HF, suggests that this biomarker could be 
used to target individuals for aggressive preventive strategies to decrease the incidence of HF 
and mortality.
Study Strengths and Potential Limitations
The findings of this study should be interpreted in the context of several strengths and 
limitations. The study utilized a well-characterized cohort of 1279 individuals with incident 
HF hospitalizations from the ARIC study, which has rigorous data collection and 
surveillance process. Both hs-cTnT levels and BMI were measured remotely prior to the HF 
diagnosis and were therefore not affected by overt myocardial dysfunction or clinically 
manifest HF/volume overload, which could otherwise confound the levels of hs-cTnT and 
BMI, respectively. On the other hand, measurement of their values too remotely may not be 
an accurate proxy of recent myocardial injury. Although only hospitalized incident HF cases 
were included in the current analysis because of lack of consistent data on outpatient HF 
through the study period, the sensitivity and positive predictive value of ICD-9 code 428.x 
for HF classified by subsequent medical record review by the ARIC criteria were 0.95 and 
0.77, respectively for combined acute decompensated HF and chronic HF (in comparison to 
0.83 and 0.78, respectively, by Framingham criteria) (21). Furthermore, there is a possibility 
of differential misclassification because HF diagnosis in obese patients may be less specific 
than in normal-weight patients. We were also not able to account for the treatment after the 
onset of HF. In addition, HF types (preserved or reduced ejection fraction) were not assessed 
for the entire study period. Finally, despite rigorous adjustment, residual confounding could 
still be possible because of non-randomized nature of the study.
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Conclusions
The presence of pre-existing sub-clinical myocardial injury (i.e., before incident HF) could 
not explain the lower mortality risk after incident HF observed in obese and overweight 
individuals compared with normal weight individuals. Future research is needed to explore 
other factors to explain the observed obesity paradox in HF even using the pre-HF obesity 
status.
Perspectives
Competency in medical knowledge
Although greater subclinical myocardial injury (assessed by high-sensitivity cardiac 
troponin-T) before heart failure increases risk of death after heart failure diagnosis, 
individuals who were obese and overweight prior to heart failure had lower risk of death 
compared with normal weight individuals after development of heart failure, irrespective of 
the presence or absence of pre-heart failure subclinical myocardial injury.
Translational Outlook
Future studies should evaluate other cardiac and non-cardiac factors including 
neurohormonal activation, metabolic reserve and other biomarkers to explain the reasons for 
the obesity paradox in heart failure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
ARIC Atherosclerosis Risk In Communities
BMI body mass index
CHD coronary heart disease
hs-cTnT cardiac troponin T measured using high-sensitivity assay
CV cardiovascular
HF heart failure
NT-proBNP N-terminal pro-B-type natriuretic peptide
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Figure 1. Development of the Study Cohort
BMI = body mass index, HF = heart failure, hs-cTnT = cardiac troponin T measured using 
high-sensitivity assay
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Figure 2. 
A. Kaplan-Meier Survival Curves by BMI groups in individuals with pre-HF hs-cTnT 
<14ng/L
B. Kaplan-Meier Survival Curves by BMI groups in individuals with pre-HF hs-cTnT 
≥14ng/L HF = heart failure, hs-cTnT = cardiac troponin T measured using high-sensitivity 
assay
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Figure 3. Hazard ratios for all-cause mortality by pre-HF BMI and hs-cTnT
Hazard ratios for each group based on reference group of normal weight with pre-HF hs-
cTnT levels <14 ng/ml.
The model was adjusted for age, gender, race, education level, health insurance, systolic 
blood pressure, physical activity, total cholesterol, current smoking, current alcohol use, 
eGFR, diabetes mellitus, hypertension, history of coronary heart disease, TIA/stroke and 
cancer.
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Table 1
Baseline characteristics of participants with incident HF hospitalization by pre-HF hs-
cTnT levels
Variable hs-cTnT <14 ng/L [N=1000] hs-cTnT ≥14 ng/L [N=279] P-value
Median hs-cTnT (ng/L) 6 (3, 9) 20 (16, 27) -
Age at incident HF (years) 74.1 (6.6) 73.1 (6.2) 0.033
Male (%) 402 (40.2) 204 (73.1) <0.001
Black (%) 263 (26.3) 88 (31.5) 0.083
Less than high school (%) 310 (31.0) 90 (32.4)
High school graduate (%) 392 (39.2) 97 (34.9) 0.398
Greater than high school (%) 297 (29.7) 91 (32.7)
BMI (kg/m2) 30.5 (6.35) 30.9 (5.79) 0.311
Normal weight 187 (18.7) 37 (13.3)
Overweight 347 (34.7) 98 (35.1) 0.089
Obese 466 (46.6) 144 (51.6)
Health Insurance (%) 785 (79.2) 211 (76.7) 0.373
Diabetes mellitus (%) 301 (30.1) 146 (52.3) <0.001
Hypertension (%) 717 (71.7) 229 (82.1) <0.001
LVH by electrocardiogram (%); n=976 45 (5.9) 24 (11.4) 0.006
Myocardial infarction (%) 64 (6.4) 41 (14.7) <0.001
Coronary heart disease (%) 148 (15.0) 75 (27.1) <0.001
Stroke/TIA (%) 139 (13.9) 43 (15.4) 0.523
Cancer (%) 133 (13.4) 50 (18.3) 0.041
Current smoking (%) 203 (20.4) 37 (13.5) 0.009
Current alcohol use (%) 415 (41.8) 101 (36.7) 0.133
Total serum cholesterol (mg/dL) 202.4 (38.33) 193.8 (48.01) 0.002
High-density lipoprotein cholesterol (mg/dL) 48.2 (16.22) 41.9 (13.34) <0.001
Triglycerides (mg/dL) 130 (95, 185) 136 (103, 204) 0.036
hs-CRP (mg/L); n=1176 3.67 (1.53, 7.33) 4.41 (1.67, 8.62) 0.029
Hemoglobin (g/dL) 13.8 (1.32) 13.8 (1.69) 0.955
NT-proBNP (pg/mL) 103 (50, 200) 177 (70, 483) <0.001
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Variable hs-cTnT <14 ng/L [N=1000] hs-cTnT ≥14 ng/L [N=279] P-value
Systolic blood pressure (mmHg) 133.4 (20.19) 136.2 (23.21) 0.053
Diastolic blood pressure (mmHg) 70.4 (11.23) 71.2 (12.95) 0.334
Heart rate (beats/min) 67.3 (10.10) 68.0 (11.17) 0.286
eGFR (ml/min/1.73m2) 84.0 (17.31) 73.3 (24.83) <0.001
Baecke sport activity score 2.44 (0.768) 2.48 (0.820) 0.432
Time to HF (years) 8.6 (3.83) 6.5 (3.56) <0.001
Data expressed as mean (standard deviation) or median (25th, 75th percentile) for continuous variables and as number (percentage) for categorical 
variables.
Time to HF is time between ARIC Visit 4 and incident HF hospitalization.
Pre-HF hs-cTnT was measured at a median of 8.3 (25th, 75th percentile 5.0, 11.4) years before the HF diagnosis.
BMI for normal weight = 18.5 to <25 kg/m2, overweight = 25 to <30 kg/m2 and obese ≥ 30 kg/m2.
BMI = body mass index, hs-cTnT = high-sensitivity cardiac troponin T, eGFR = estimated glomerular filtration rate, HF = heart failure, hs-CRP = 
high-sensitivity C reactive protein, LVH = left ventricular hypertrophy, NT-proBNP = N-terminal pro-B-type natriuretic peptide, TIA = transient 
ischemic attacks.
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Table 2
Hazard ratios for all-cause mortality after incident HF hospitalization by pre-HF BMI 
and pre-HF hs-cTnT
BMI Category [Died/HF=%] 
[579/1279=45.2%]
hs-cTnT <14 ng/L* [405/1000=40.5%] 
Adjusted HR (95% CI)
hs-cTnT ≥14 ng/L [174/279=62.4%] 
Adjusted HR (95% CI)
Normal weight [115/224=51.3%] [88/187=47.1%] Reference=1 [27/37=73.0%] Reference=1
Overweight [208/445=46.7%] [151/347=43.5%] 0.69 (0.48-0.98) [57/98=58.2%] 0.50 (0.30-0.83)
Obese [256/610=41.9%] [166/466=35.6%] 0.50 (0.35-0.72) [90/144=62.5%] 0.56 (0.34-0.91)
For each hs-cTnT category reference is the normal weight group. BMI for normal weight = 18.5 to <25 kg/m2, overweight = 25 to <30 25 kg/m2 
and obese≥ 30 25 kg/m2. Model adjusted for age, gender, race, education level, health insurance, systolic blood pressure, physical activity, total 
cholesterol, current smoking, current alcohol use, eGFR, diabetes mellitus, hypertension, history of coronary heart disease, TIA/stroke and cancer.
*
Proportional hazard assumption was violated in the hs-cTnT <14 stratum; time-dependent term of group*log (time in years) was included in 
adjusted models in this group.
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